ONCTERNAL THERAPEUTICS is a biopharmaceutical company with two promising anti-cancer drugs in early clinical trials. The first asset, Cirmtuzumab (anti-ROR1 antibody), is enrolling patients in a Phase 1 trial against Chronic Lymphocytic Leukemia (CLL) and is largely funded by an $18.2 million grant from the California Institute of Regenerative Medicine. The second asset, TK216, is a first-in-class small molecule targeted at pediatric cancers. TK216 is currently in a Phase 1b trial in Ewing Sarcoma and getting ready for a 2018 Phase 1 trial in Acute Myeloid Leukemia (AML) at MD Anderson.